A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety …

L Eric, CJ Yeo, KD Lillemoe, B Biedrzycki… - Annals of …, 2011 - journals.lww.com
L Eric, CJ Yeo, KD Lillemoe, B Biedrzycki, B Kobrin, J Herman, E Sugar, S Piantadosi
Annals of surgery, 2011journals.lww.com
Purpose: Surgical resection provides the only possibility of cure for pancreas cancer. A
standard adjuvant approach has not been established. We tested the safety and efficacy of a
granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy
administered in patients with resected pancreatic adenocarcinoma. Patients and Methods: A
single institution phase II study of 60 patients with resected pancreatic adenocarcinoma was
performed. Each immunotherapy treatment consisted of a total of 5× 108 GM-CSF-secreting …
Purpose: Surgical resection provides the only possibility of cure for pancreas cancer. A standard adjuvant approach has not been established. We tested the safety and efficacy of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy administered in patients with resected pancreatic adenocarcinoma. Patients and Methods: A single institution phase II study of 60 patients with resected pancreatic adenocarcinoma was performed. Each immunotherapy treatment consisted of a total of 5× 108 GM-CSF-secreting cells distributed equally among 3 lymph node regions. The first immunotherapy treatment was administered 8 to 10 weeks after surgical resection. Subsequently, patients received 5-FU based chemoradiation. Patients who remained disease-free after completion of chemoradiotherapy received treatments 2 to 4, each 1 month apart. A fifth and final booster was administered 6 months after the fourth immunotherapy. The primary endpoint was disease free survival and secondary
Lippincott Williams & Wilkins